Please wait while we load the requested 10-Q report or click the link below:
Announced in May 2016 the proposed merger with Takara Bio USA Holdings Inc. and certain of its affiliates, pursuant to which Takara would acquire the Company for a multiple of the Company’s 2016 revenue, subject to certain adjustments set forth in the merger agreement
Entered into a distribution agreement under which Takara has begun to distribute WaferGen’s products in Japan
Exceeded $2.5 million in quarterly revenue for the first time since WaferGen’s operations began
Placed four ICELL8™ Single-Cell Systems in the second quarter of 2016
Received a Notice of Allowance for a U.S. Patent Application for both method and system claims to process genetic material including single cell NGS libraries from multi-well arrays; consequently, WaferGen now owns five total issued patents and two allowed applications
Closed on June 30, 2016, with $7.4 million in cash, which WaferGen believes is sufficient to fund operations into 2017
The following information was filed by Wafergen Biosystems, Inc. (WGBS) on Tuesday, August 9, 2016 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-Q Quarterly Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one quarter to another to evaluate Wafergen Biosystems, Inc.'s financial trajectory
Compare this 10-Q Quarterly Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Wafergen Biosystems, Inc..